PetMed Express FY2025 net sales $227M, net loss $6.3M; Q1/Q2 filings delayed

PETMED EXPRESS INC

2026-Q2 EPS reported -$2.05 revenue$95,544,000

Net sales of $227.0M for FY2025 below preliminary range of $231.6M-$233.6M due to restatement of promotional sales reimbursements to cost of sales.
Net loss of $6.3M widened from preliminary estimated loss of $4.5M-$5.0M, driven by a $1.2M non-cash impairment charge for intangible assets.
Cash balance of $54.7M and no debt as of March 31, 2025.
Company filed Form 10-K; plans to file Q1 and Q2 2025 reports and resume normal quarterly earnings call cadence.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001040130-25-000074
form_type: 8-K
ticker: PETS
cik: 0001040130
company_name: PETMED EXPRESS INC
filed_at: 2025-10-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.620425+00:00
generated_at: 2026-05-17T03:50:25.105105+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001040130-25-000074
json_url: https://secwatch.observer/filing/0001040130-25-000074.json
markdown_url: https://secwatch.observer/filing/0001040130-25-000074.md
text_url: https://secwatch.observer/filing/0001040130-25-000074.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1040130/000104013025000074/0001040130-25-000074-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1040130/000104013025000074/pets-20251014.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001040130-25-000074

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.